One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Gossamer Bio logo
Gossamer Bio GOSS
$ 9.54 -4.12%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

Gossamer Bio Financial Statements 2025-2011 | GOSS

Annual Financial Statements Gossamer Bio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

107 M 106 M 221 M 83.7 M 718 M 692 M 741 M - - - - - - - -

Shares

229 M 226 M 153 M 84.6 M 74.8 M 68.5 M 54.7 M - - - - - - - -

Historical Prices

0.47 0.47 1.45 0.99 9.59 10.1 13.3 - - - - - - - -

Net Income

-170 M -56.5 M -180 M -229 M -234 M -243 M -180 M -147 M -6.77 M -83 K - - - - -

Revenue

48.5 M 115 M - - - - - - - - - - - - -

Operating Income

-171 M -59.9 M -184 M -219 M -216 M -234 M -186 M -149 M -6.65 M - - - - - -

Interest Expense

9.29 M 14 M 13.5 M 13.9 M 19.4 M 12.7 M 1.94 M 12 K - - - - - - -

EBITDA

-171 M -59.1 M -182 M -217 M -214 M -233 M -183 M -97 M -1.15 M -83 K - - - - -

Operating Expenses

219 M 175 M 184 M 219 M 216 M 234 M 186 M - - - - - - - -

General and Administrative Expenses

37.6 M 36.1 M 38.5 M 47.6 M 45.8 M 49.7 M 39.1 M 44.1 M 262 K 83 K - - - - -

All numbers in USD currency

Quarterly Income Statement Gossamer Bio

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

227 M 234 M - 228 M 227 M 227 M 227 M 226 M 226 M 226 M 225 M 193 M 95.4 M 94.9 M 94.4 M 91.2 M 76.7 M 75.9 M 75.8 M 75 M 74.7 M 74.1 M 73.9 M 72.2 M 66.6 M 61.9 M 61.6 M 60.8 M 60.3 M 36.3 M 8.05 M 6.42 M 5.8 M 5.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-38.3 M -46.7 M - -48.2 M -38.3 M -36.6 M - -30.8 M 49.2 M -41.9 M - -40 M -42.5 M -49.2 M - -59.4 M -56.5 M -57.8 M - -60.2 M -59.8 M -57.6 M - -57.8 M -66.9 M -54.1 M -54.7 M -48.5 M -44.5 M -32.6 M -38.8 M -49.4 M -32.7 M -26 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

11.5 M 17 M - 13.3 M 11.5 M 9.89 M - 9.48 M 95.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-38.8 M -44.9 M - -49.1 M -38.8 M -36.8 M - -33.9 M 52.1 M -42 M - -40.5 M -46.3 M -47.9 M - -56 M -53.9 M -54.3 M - -55.7 M -55.6 M -53.2 M - -53.6 M -65.3 M -55 M -55.8 M -50 M -46.3 M -34 M -39.8 M -50 M -33 M -26.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

2.69 M 603 K - 2.95 M 2.69 M 2.62 M - 4.29 M 2.75 M 2.82 M - 3.42 M 6.54 M 3.5 M - 3.48 M 3.48 M 3.47 M - 4.89 M 4.83 M 4.78 M - 4.72 M 2.49 M 707 K - - - 19 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-38.8 M -44.9 M - - - -36.8 M - -33.7 M 52.4 M -41.7 M - -40.1 M -45.8 M -47.5 M - -55.5 M -53.4 M -53.9 M - -55.2 M -55.2 M -52.8 M - -52.5 M -64.7 M -54.6 M -55.8 M -49.4 M -46 M -33.8 M -39.8 M -49.9 M -33 M -26.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

50.3 M 61.8 M - 62.4 M 50.3 M 46.7 M - 43.4 M 43.8 M 42 M - 40.5 M 46.3 M 47.9 M - 56 M 53.9 M 54.3 M - 55.7 M 55.6 M 53.2 M - 53.6 M 65.3 M 55 M - 50 M 46.3 M 34 M - 50 M 33 M 26.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

8.68 M 18.7 M - 9.39 M 8.68 M 8.66 M - 8.5 M 8.67 M 9.57 M - 9.29 M 9.98 M 10.1 M - 11.5 M 11.3 M 12 M - 12.5 M 11.3 M 11.3 M - 11.4 M 11.7 M 10.7 M - 9.84 M 9.67 M 8.03 M - 22.9 M 4.61 M 2.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Gossamer Bio GOSS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Gossamer Bio plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 41.75 -0.12 % $ 47.8 B israelIsrael
Molecular Templates Molecular Templates
MTEM
- -23.43 % $ 495 K usaUSA
Genmab A/S Genmab A/S
GMAB
$ 52.76 -4.28 % $ 3.41 B danmarkDanmark
GeoVax Labs GeoVax Labs
GOVX
$ 0.16 -2.44 % $ 153 K usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.49 -1.39 % $ 5.77 B spainSpain
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.07 9.81 % $ 855 K usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 50.38 -1.51 % $ 204 B britainBritain
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 4.6 -9.88 % $ 39.2 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
- -1.56 % $ 12.3 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 4.09 -6.31 % $ 1.31 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
- -48.37 % $ 3.71 M usaUSA
Annovis Bio Annovis Bio
ANVS
$ 0.64 -46.19 % $ 13.2 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
- - $ 218 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Global Blood Therapeutics Global Blood Therapeutics
GBT
- - $ 4.62 B usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 565.49 -7.07 % $ 25.1 B usaUSA
Inozyme Pharma Inozyme Pharma
INZY
- - $ 207 M usaUSA
Veracyte Veracyte
VCYT
$ 23.51 -55.24 % $ 1.85 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 25.78 -7.83 % $ 2.9 B usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 3.08 -10.85 % $ 32.8 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 28.53 -1.81 % $ 2.91 B usaUSA
NanoString Technologies NanoString Technologies
NSTG
- -37.43 % $ 5.1 M usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
- -29.58 % $ 126 M usaUSA
Surface Oncology Surface Oncology
SURF
- - $ 59.7 M usaUSA
Immunome Immunome
IMNM
$ 17.86 -8.5 % $ 1.56 B usaUSA
Immuron Limited Immuron Limited
IMRN
$ 0.85 -0.01 % $ 196 M australiaAustralia
Sierra Oncology Sierra Oncology
SRRA
- -0.05 % $ 1.34 B canadaCanada
Immunic Immunic
IMUX
$ 7.44 -6.3 % $ 1.16 B usaUSA
Incyte Corporation Incyte Corporation
INCY
$ 118.15 -3.83 % $ 23.1 B usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.0 -0.99 % $ 11.3 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.2 -5.83 % $ 342 M usaUSA
Vaccinex Vaccinex
VCNX
- -61.37 % $ 654 K usaUSA
INmune Bio INmune Bio
INMB
$ 1.18 -11.14 % $ 29.2 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
$ 3.06 -5.56 % $ 129 M usaUSA
Xencor Xencor
XNCR
$ 34.0 -2.94 % $ 2.52 B usaUSA
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Zai Lab Limited Zai Lab Limited
ZLAB
$ 22.61 -0.83 % $ 24.8 B chinaChina
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 1.72 -2.56 % $ 124 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA